Reducing unnecessary medications in elderly patients with multiple prescriptions

Patient-centred Deprescribing of Psychotropic, Sedative and Anticholinergic Medication in Elderly Patients With Polypharmacy: a Cluster-randomised Trial

NA · Ludwig-Maximilians - University of Munich · NCT05842928

This study tests a new way to help older adults with multiple prescriptions cut down on unnecessary medications by working closely with their doctors and pharmacists.

Quick facts

PhaseNA
Study typeInterventional
Enrollment352 (estimated)
Ages65 Years and up
SexAll
SponsorLudwig-Maximilians - University of Munich (other)
Locations3 sites (Bielefeld and 2 other locations)
Trial IDNCT05842928 on ClinicalTrials.gov

What this trial studies

The PARTNER study evaluates a patient-centered approach to reduce the use of potentially inappropriate medications among elderly patients who are taking multiple drugs. It involves collaboration between general practitioners and community pharmacists to provide education, workshops, and shared decision-making processes. Participants will receive a comprehensive medication review and empowerment strategies to manage their prescriptions effectively. The study compares this intervention to a control group that only receives a basic medication review.

Who should consider this trial

Good fit: Ideal candidates are elderly patients aged 65 and older who are currently taking five or more medications, including at least one potentially inappropriate medication.

Not a fit: Patients with terminal illnesses, severe physical or mental health conditions, or those unable to participate in the study due to their health status may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could significantly improve medication safety and quality of life for elderly patients by reducing the risks associated with polypharmacy.

How similar studies have performed: Other studies have shown success in similar approaches to deprescribing and medication management in elderly populations, indicating a promising avenue for improving patient outcomes.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Aged 65 years or older
* Patient is capable of giving consent
* GP contact in the quarter prior to inclusion
* Current use of ≥ 5 drugs, including ≥ 1 PSA-PIM (hypnotics, opioids, gabapentinoids, antipsychotics, antidepressants, anticholinergic urospasmolytics) with a treatment duration of ≥ 6 months
* Willingness to select a regular pharmacy for the study period
* Consent to data exchange between GP and community pharmacy

Exclusion Criteria:

* Terminal illness (life expectancy \< 6 months)
* Current treatment of pain associated with cancer
* Other serious physical illness or mental distress (e.g. bereavement) that makes participation in the study impossible (according to the GP's assessment)
* Psychiatric illness or addiction that makes participation in the study impossible (according to the GP's assessment)
* Unable to meet the requirements of the study (participation in telephone or written questionnaires, visits to the GP practice or community pharmacy, alone or with the help of caregivers for physical infirmity)
* Current participation in research projects on medication safety or geriatric medicine

Where this trial is running

Bielefeld and 2 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Deprescriptions, Antidepressive Agents, Antipsychotic Agents, Analgesics, Opioid, Hypnotics and Sedatives, Cholinergic Antagonists, Polypharmacy, General Practice

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.